<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218423</url>
  </required_header>
  <id_info>
    <org_study_id>SPR 0028</org_study_id>
    <nct_id>NCT03218423</nct_id>
  </id_info>
  <brief_title>Longitudinal Performance of Epi proColon</brief_title>
  <acronym>PERT</acronym>
  <official_title>Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epigenomics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epigenomics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate longitudinal performance of Epi proColon with respect to test&#xD;
      positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up&#xD;
      colonoscopy and diagnostic yield, as well as assay failure rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epi proColon is blood based screening test for colorectal cancer that is FDA - PMA approved.&#xD;
      It is indicated for average risk patients who are unwilling or unable to be screened with&#xD;
      other recommended screening tests, including colonoscopy or fecal occult blood tests.&#xD;
&#xD;
      The PERT study is designed to assess the test performance of Epi proColon when it is used&#xD;
      annually for two consecutive years. Subjects enrolled in the study will be offered initial&#xD;
      testing. Subjects with a positive result will be referred for colonoscopy. Subjects with a&#xD;
      negative test result will be encouraged to be screened the following year. At the one year&#xD;
      interval, test negative subjects will be reminded to be rescreened. Subjects with a positive&#xD;
      test will be referred for colonoscopy, while subjects with a negative test will be be&#xD;
      encouraged to participate in a screening program in subsequent years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in test specificity between initial testing and repeat testing 1 year</measure>
    <time_frame>Through study completion, expected at 60 months</time_frame>
    <description>Subjects will be tested with blood-based Epi proColon assay at initial enrollment, and tested again 1 year later (positive or negative test results)&#xD;
Subjects with positive test results with Epi proColon assay are referred to colonoscopy. Colonoscopy outcomes will be recorded (no evidence of disease or CRC)&#xD;
The difference in test specificity between initial and follow-up visits will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of colorectal cancer</measure>
    <time_frame>Through study completion, expected at 60 months</time_frame>
    <description>Findings of colorectal cancer in subjects with a colonoscopy following a positive Epi proColon test will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to testing</measure>
    <time_frame>Through study completion, expected at 60 months</time_frame>
    <description>The adherence to repeated Epi proColon testing by patients who had a negative initial Epi proColon result will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to colonoscopy</measure>
    <time_frame>Through study completion, expected at 60 months</time_frame>
    <description>The rate of adherence to colonoscopy for patients with a positive Epi proColon result will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Yield</measure>
    <time_frame>Through study completion, expected at 60 months</time_frame>
    <description>All procedure results will be recorded for patients who complete a colonoscopy evaluation following a positive Epi proColon test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay Failure Rate</measure>
    <time_frame>Through study completion, expected at 60 months</time_frame>
    <description>The Epi proColon assay failure rate will be recorded during the duration of the study</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epi proColon</intervention_name>
    <description>Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be the population defined in the intended use statement, i.e.&#xD;
        adults of either sex, 50 years or older, defined as average risk for CRC, who have been&#xD;
        offered and have a history of not completing CRC screening. Tests that are available and&#xD;
        recommended in the USPSTF 2008 CRC screening guidelines will be offered and declined prior&#xD;
        to offering the Epi proColon test.&#xD;
&#xD;
        Eligible subjects will be recruited at a regular visit at their primary health care&#xD;
        provider, or through typical preventive care outreach by health care providers. Consented&#xD;
        subjects who agree to participate in the study and agree to be tested with Epi proColon&#xD;
        will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Average-risk subjects (no family history of colorectal cancer (CRC), no personal&#xD;
             history of polyps or CRC).&#xD;
&#xD;
          -  Subjects who have a history of non-compliance for CRC screening.&#xD;
&#xD;
          -  After proper counseling by a health care provider, subjects who declined colonoscopy&#xD;
             and FIT testing.&#xD;
&#xD;
          -  Subjects who are 50 years of age or greater, but less than 75 years old.&#xD;
&#xD;
          -  Subjects who are able to understand and sign written informed consent (IC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects defined as having elevated risk for developing CRC based on previous history&#xD;
             of colorectal polyps, CRC or related cancers, inflammatory bowel disease (IBD).&#xD;
&#xD;
          -  Subjects with a family history of CRC, particularly with two or more first degree&#xD;
             relatives with CRC, or one or more first degree relative(s) less than 50 years of age&#xD;
             with CRC.&#xD;
&#xD;
          -  Subjects who have been diagnosed with a relevant familial (hereditary) cancer&#xD;
             syndrome, such as familial adenomatous polyposis (FAP) or non-polyposis colorectal&#xD;
             cancer (HNPCC or Lynch Syndrome), Peutz-Jeghers Syndrome, MYH-Associated Polyposis&#xD;
             (MAP), Gardner's syndrome, Turcot's (or Crail's) syndrome, Cowden's syndrome, Juvenile&#xD;
             Polyposis, Cronkhite-Canada syndrome, Neurofibromatosis, or Familial Hyperplastic&#xD;
             Polyposis, or in patients with anorectal bleeding, hematochezia, or with known iron&#xD;
             deficiency anemia.&#xD;
&#xD;
          -  Subjects who are up to date for CRC screening (FOBT within preceding 12 months,&#xD;
             flexible sigmoidoscopy or double contrast barium enema within 5 years, or colonoscopy&#xD;
             within 10 years).&#xD;
&#xD;
          -  Subjects with comorbid illness precluding endoscopic evaluation (coronary artery&#xD;
             disease with myocardial infarction within 6 months, unstable angina or congestive&#xD;
             heart failure, chronic obstructive pulmonary disease requiring home oxygen, other&#xD;
             diseases that limit life expectancy to less than 10 years).&#xD;
&#xD;
          -  Subjects with chronic gastritis, or who have cancer other than colorectal, or pregnant&#xD;
             women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo deVos, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Epigenomics, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theo deVos, PhD</last_name>
    <phone>2068832916</phone>
    <email>theo.devos@epigenomics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neil Mucci</last_name>
    <email>neil.mucci@globalbioclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Veterans Affairs San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Goodman</last_name>
      <phone>858-552-8585</phone>
      <phone_ext>6797</phone_ext>
      <email>Debora.Goodman@va.gov</email>
    </contact>
    <investigator>
      <last_name>Samir Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Health System</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Barger-Smith</last_name>
      <phone>248-551-1556</phone>
      <email>karen.barger-smith@beaumont.org</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Cooney</last_name>
      <phone>248-551-0099</phone>
      <email>maureen.cooney@beaumont.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandra Halalau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Macor</last_name>
      <phone>732-235-8143</phone>
      <email>macorma@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Greg Riedlinger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Leathers</last_name>
      <phone>919-668-5589</phone>
      <email>kimberly.leathers@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Chmielewski</last_name>
      <phone>919-668-7863</phone>
      <email>kathy.chmielewski@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ranee Chatterjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Reiner, MPH, BSN, RN</last_name>
      <phone>570-214-5421</phone>
      <email>kmreiner1@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Howell-Harte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Krupp</last_name>
      <phone>304-581-1913</phone>
      <email>jennifer.krupp@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Dorian Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130001</url>
    <description>FDA Epi proColon product page</description>
  </link>
  <reference>
    <citation>Potter NT, Hurban P, White MN, Whitlock KD, Lofton-Day CE, Tetzner R, Koenig T, Quigley NB, Weiss G. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014 Sep;60(9):1183-91. doi: 10.1373/clinchem.2013.221044. Epub 2014 Jun 17.</citation>
    <PMID>24938752</PMID>
  </reference>
  <reference>
    <citation>Johnson DA, Barclay RL, Mergener K, Weiss G, KÃ¶nig T, Beck J, Potter NT. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014 Jun 5;9(6):e98238. doi: 10.1371/journal.pone.0098238. eCollection 2014.</citation>
    <PMID>24901436</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screening</keyword>
  <keyword>plasma</keyword>
  <keyword>DNA methylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

